Market Exclusive

Analyst Activity – Credit Suisse Group Raises Its Price Target On Alnylam Pharmaceuticals (NASDAQ:ALNY) to $154.00

Analyst Ratings For Alnylam Pharmaceuticals (NASDAQ:ALNY)

Today, Credit Suisse Group raised its price target on Alnylam Pharmaceuticals (NASDAQ:ALNY) to $154.00 per share.

Some recent analyst ratings include

Recent Insider Trading Activity For Alnylam Pharmaceuticals (NASDAQ:ALNY)
Alnylam Pharmaceuticals (NASDAQ:ALNY) has insider ownership of 4.30% and institutional ownership of 92.44%.

Recent Trading Activity for Alnylam Pharmaceuticals (NASDAQ:ALNY)
Shares of Alnylam Pharmaceuticals closed the previous trading session at with 132367 shares trading hands.

Exit mobile version